# A Randomized Phase 1 Study of Liralutide Injection in Healthy Chinese Subjects

> **NCT05225974** · PHASE1 · COMPLETED · sponsor: **The Affiliated Hospital of Qingdao University** · enrollment: 32 (actual)

## Conditions studied

- Therapeutic Equivalency

## Interventions

- **DRUG:** Liraglutide injection
- **DRUG:** Liraglutide injection(Victoza®)

## Key facts

- **NCT ID:** NCT05225974
- **Lead sponsor:** The Affiliated Hospital of Qingdao University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-16
- **Primary completion:** 2021-07-30
- **Final completion:** 2021-08-19
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2022-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05225974

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05225974, "A Randomized Phase 1 Study of Liralutide Injection in Healthy Chinese Subjects". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05225974. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*